Procept BioRobotics appoints cardiac surgeon Michael Mack to board

• Procept BioRobotics expanded its board to 10 directors on Oct. 2, 2026, naming cardiac surgeon Michael Mack to the new seat.
• Mack was appointed a Class II director, with a term running through the 2029 annual stockholder meeting.
• He has practiced in Dallas since 1982, chairs Baylor Scott & White Research Institute, holds senior roles across U.S. cardiothoracic groups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-064586), on October 02, 2026, and is solely responsible for the information contained therein.